The Alliance for Regenerative Medicine Releases Q1 2018 Data Report, Highlighting Sector Trends and Metrics

WASHINGTON, D.C. – May 10, 2018

The Alliance for Regenerative Medicine (ARM) today released its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the first quarter of 2018.

ARM and Informa have partnered to create a regenerative medicine-specific database, currently tracking more than 861 cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide. To create its quarterly data reports, ARM further analyzes this data to reveal industry-specific statistics and trends, including total financings, partnerships and other deals, clinical trial information, and key clinical data milestones.

The Q1 2018 data report also features commentary from ARM’s recently held State of the Industry program, including insights from panelists Bill Lundberg, Chief Scientific Officer, CRISPR Therapeutics; Pascal Touchon, SVP and Global Head, Cell and Gene, Novartis Oncology; and Deepak Srivastava, President, Gladstones Institute.

“We have had great energy in the sector since the start of the year,” said Janet Lynch Lambert, ARM’s Chief Executive Officer. “Clinically and commercially, therapeutic developers are moving ahead at a strong pace, with tremendous optimism. There are still plenty of challenges, but we’re excited about the many opportunities ahead.”

Highlighted findings from the Q1 2018 data report include:

  • Globally, companies active in gene and cellular therapies and other regenerative medicines raised more than $3.8 billion in the first quarter of 2018, a 135% increase from Q1 2017. The report also includes financial data broken out by technology type and financing type.
  • There were 959 clinical trials underway worldwide at the close of the first quarter of 2018, with more than 53 percent of those in oncology and nearly 10 percent in cardiovascular disorders. The report also includes figures on clinical trials by phase and indication, as well as by technology type.

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers, and clinical data events.

The report is available online here. For more information, please visit or contact Lyndsey Scull at

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 290 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit